← all works
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Rheumatoid Arthritis Research and Therapies
- Field
- Medicine
- Canadian institutions
- Université Laval
- Funders
- Chugai Pharmaceutical
- Keywords
- TocilizumabMedicineRheumatoid arthritisPlaceboInternal medicineClinical endpointRheumatologyMethotrexatePopulationRandomized controlled trialArthritisGastroenterologyPathology
- Has abstract in OpenAlex
- no